endpoint was 6.5% in the BES arm vs 7.1% in the EES arm (pϭNS). Between the BES and EES arm no significant differences were observed in cardiac death 0.5% vs 1.3%, MI 4.5% vs 5.4%, TVR 3.5% vs 2.7% and TLR 2.7% vs 2.2, respectively. Definite and probable stent thrombosis rate was 0.74% in BES and 1.79% in EES (pϭ0.25). Conclusions: Despite high complexity of lesions in the LL subgroup, good clinical outcomes and low rate of revascularization were observed at 12 months post-procedure with both types of drug eluting stents. Stent thrombosis rate was relatively low despite multiple overlapping stents. Our findings confirm the safety efficacy of both drug-eluting stents for treatment of patients with long lesions in coronary arteries.
Professor Interventional Cardiology, Rotterdam, The Netherlands
Background: To investigate with coronary CT angiography the mid-term outcome of a percutaneously implanted, bio-resorbable, coronary scaffolding device.
Methods: As part of the ABSORB trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of de Novo Native Coronary
Artery Lesions) 71 patients underwent non-invasive coronary CT angiography 18 months after implantation of an everolimus eluting, bio-resorbable scaffold (BVS 1.1, Abbott Vascular, Santa Clara, CA) for treatment of obstructive coronary artery disease. Using semi-automatic vessel extraction, cross-sectional lumen and vessel areas were measured at 1-mm longitudinal intervals including 5 mm beyond the scaffold borders. Acquired MSCT data was further processed for calculation of fractional flow reserve in another independent corelab (Heart Flow, CA, USA). Results: At 180 days there were no deaths, three non-Q-wave myocardial infarctions and four ischemia driven target lesion revascularizations. CT angiographic image quality allowed qualitative evaluation in 67 patients, and quantitative evaluation in 61 patients. The mean lumen area within the scaffolded site was 5.1 Ϯ 1.4 mm2, compared to the 7.1-mm2 nominal cross-sectional scaffold area. The average minimal lumen area measured 3.5 Ϯ 1.0 mm2, and the area stenosis was 23 Ϯ 22% (range -64.2 -72.0%). Significant coronary obstruction was qualitatively assessed in a single patient. The mean plaque area (vessel minus lumen area) measured 8.9 Ϯ 3.4 mm2. Coronary lumen enlargement up to 13.3 mm2 was observed in one other patient. The non-invasive functional assessment (functional flow reserve according to MSCT) is ongoing and the complete results will be presented at the time of meeting. Conclusions: Noninvasive evaluation by cardiac CT demonstrated good angiographic results 18 months after implantation of a bio-absorbable coronary scaffolding device. The feasibility of non-invasive FFR will be presented at the time of meeting.
TCT-582
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Background:
The MiStent SES (Micell Technologies, Durham, NC) is an investigational DES characterized by use of crystalline sirolimus and a fully absorbable polymer on a thin strut (64um) cobalt-chromium stent. The stent coating is eliminated from the stent in 45-60 days with full absorption of the polymer by 90 days. The DESSOLVE I FIH clinical trial was designed to evaluate the initial and long-term efficacy and safety of the MiStent SES in a defined group of patients. Methods: The DESSOLVE I FIH clinical trial is a single-arm study conducted at 5 international sites. Thirty patients with discrete de novo lesions (2.5-3.5 mm vessel diameter and Յ20 mm length) in native coronary arteries were implanted with a single MiStent SES. The patients had a primary intervention at either of 4-months, 6-months or 8-months with a subsequent intervention at 18-months. Angiography and IVUS were used to evaluate the amount of neointimal hyperplasia and stent apposition, and OCT for vessel healing and stent coverage. Clinical events were assessed at 8-months, 12-months and 18-months. Results: The initial 4-months, 6-month and 8-month evaluations demonstrated an in-stent LLL of 0.01, 0.21 and 0.10 respectively as assessed by core laboratory quantitative angiography. Imaging with OCT demonstrated thin, homogenous coverage with high rates of stent strut coverage at 6 and 8 months, 93% and 96%, with a low rate of stent strut malapposition. The IVUS findings supported minimal neointimal hyperplasia with a neointimal volume index of 0.8mm3/mm at 8 months. Long-term clinical outcomes and angiographic, OCT and IVUS analyses at 18-months will be presented.
Conclusions:
The MiStent SES demonstrates sustained efficacy and safety through 18 months post-procedure. 
TCT

Background:
To evaluate the safety and effectiveness of the Elixir DESyneTM BD Novolimus Eluting Coronary Stent System (CSS) with a bioabsorbable polymer compared to the Endeavor Zotarolimus Eluting Coronary Stent System through the assessment of clinical, angiographic, and IVUS endpoints. Methods: A total of 149 patients were randomized 3:1, either to the Elixir DESyne BD Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the Endeavor Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were analyzed for the primary endpoint of in-stent late lumen loss (LLL) assessed by QCA at 6 months. Moreover, all patients underwent evaluation for the secondary endpoints including the Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for angiographic endpoints at 6 months including: in-segment LLL, percent diameter stenosis, minimal lumen diameter post-procedure and at 6 months, and angiographic binary restenosis (ABR) (Ն50%). A subset of patients underwent intravascular ultrasound (IVUS) evaluation including percent (%) neointimal obstruction at 6 months. Results: The study met the primary endpoint demonstrating both non-inferiority and superiority of the DESyne BD compared to the control (0.12Ϯ0.15 vs 0.67Ϯ0.47, pϽ0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs 7.9%, pϭ0.003). Excellent clinical results at 6 months were demonstrated for both devices. Clinical results through 12 months and additional angiographic and IVUS results will be presented.
Conclusions:
The study met the primary endpoint demonstrating both non-inferiority and superiority of the DESyne BD compared to the control. Clinical results through 12 months and complete angiographic and IVUS results will be presented.
TCT-584
Nine , John Ormiston as stent thrombosis. These events are hypothesized to be associated in part with durable polymers of current DES. The MiStent SES uses a unique combination of components, a crystalline formulation of sirolimus and a fully absorbable polymer on a thin-strut, cobalt chromium stent platform. The polymer coating is eliminated from the stent in 45-60 days with complete absorption in 90 days. Sirolimus is simultaneously released into the surrounding tissue as a controlled elution. Methods: The DESSOLVE II clinical trial is a 2:1 randomized study conducted at 26 sites evaluating the MiStent SES for superiority in late lumen loss as compared to the control stent, the Medtronic Endeavor Sprint (Santa Rosa, CA). Patients with discrete de novo lesions (2.5-3.5 mm vessel diameter and Յ27 mm length) in native coronary arteries were acceptable for inclusion in the trial. A total of 183 patients were randomized into either the MiStent SES or Endeavor Sprint and patients had follow-up at 30-days, 6, 9, and 12-months post-procedure. Angiography was conducted at 9-months with two subgroups: 38 patients imaged using optical coherence tomography (OCT) and 29 patients participated in endothelial function testing (EFT). Results: The MiStent SES was superior to Endeavor for the primary endpoint analysis of late lumen loss. The OCT revealed a mean of 2% uncovered struts with good suppression on neointimal hyperplasia. EFT demonstrated an overall return of endothelial function with no incidence of vasoconstriction in either the test or control group. Additional secondary endpoint data will be presented.
Conclusions:
The MiStent SES is an innovative drug eluting stent with sirolimus in a fully absorbable polymer demonstrating a superior performance as compared to the Endeavor Sprint DES. OCT shows stent coverage at 9-months with a return of endothelial function.
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